A Small Peptide Ac-SDKP Inhibits Radiation-Induced Cardiomyopathy

Circ Heart Fail. 2018 Aug;11(8):e004867. doi: 10.1161/CIRCHEARTFAILURE.117.004867.

Abstract

Background: Advances in radiotherapy for thoracic cancers have resulted in improvement of survival. However, radiation exposure to the heart can induce cardiotoxicity. No therapy is currently available to inhibit these untoward effects. We examined whether a small tetrapeptide, N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP), can counteract radiation-induced cardiotoxicity by inhibiting macrophage-dependent inflammatory and fibrotic pathways.

Methods and results: After characterizing a rat model of cardiac irradiation with magnetic resonance imaging protocols, we examined the effects of Ac-SDKP in radiation-induced cardiomyopathy. We treated rats with Ac-SDKP for 18 weeks. We then compared myocardial contractile function and extracellular matrix by cardiac magnetic resonance imaging and the extent of inflammation, fibrosis, and Mac-2 (galectin-3) release by tissue analyses. Because Mac-2 is a crucial macrophage-derived mediator of fibrosis, we performed studies to determine Mac-2 synthesis by macrophages in response to radiation, and change in profibrotic responses by Mac-2 gene depleted cardiac fibroblasts after radiation. Cardiac irradiation diminished myocardial contractile velocities and enhanced extracellular matrix deposition. This was accompanied by macrophage infiltration, fibrosis, cardiomyocyte apoptosis, and cardiac Mac-2 expression. Ac-SDKP strongly inhibited these detrimental effects. Ac-SDKP migrated into the perinuclear cytoplasm of the macrophages and inhibited radiation-induced Mac-2 release. Cardiac fibroblasts lacking the Mac-2 gene showed reduced transforming growth factor β1, collagen I, and collagen III expression after radiation exposure.

Conclusions: Our study identifies novel cardioprotective effects of Ac-SDKP in a model of cardiac irradiation. These protective effects are exerted by inhibiting inflammation, fibrosis, and reducing macrophage activation. This study shows a therapeutic potential of this endogenously released peptide to counteract radiation-induced cardiomyopathy.

Keywords: cardiomyopathies; fibrosis; inflammation; macrophages; radiotherapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Cardiomyopathies / diagnostic imaging
  • Cardiomyopathies / metabolism
  • Cardiomyopathies / pathology
  • Cardiomyopathies / prevention & control*
  • Cardiotoxicity
  • Collagen Type I / metabolism
  • Collagen Type III / metabolism
  • Disease Models, Animal
  • Extracellular Matrix / drug effects
  • Extracellular Matrix / metabolism
  • Female
  • Fibrosis
  • Galectin 3 / genetics
  • Galectin 3 / metabolism
  • Macrophages / drug effects*
  • Macrophages / metabolism
  • Macrophages / pathology
  • Magnetic Resonance Imaging
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Oligopeptides / pharmacology*
  • RAW 264.7 Cells
  • Radiation Injuries / diagnostic imaging
  • Radiation Injuries / metabolism
  • Radiation Injuries / pathology
  • Radiation Injuries / prevention & control*
  • Radiation-Protective Agents / pharmacology*
  • Rats, Sprague-Dawley
  • Transforming Growth Factor beta1 / metabolism
  • Ventricular Function, Left / drug effects

Substances

  • Collagen Type I
  • Collagen Type III
  • Galectin 3
  • Lgals3 protein, mouse
  • Lgals3 protein, rat
  • Oligopeptides
  • Radiation-Protective Agents
  • Tgfb1 protein, mouse
  • Transforming Growth Factor beta1
  • goralatide